Therapeutic area intelligence for Severe Pneumonia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

MiNK Therapeutics →

Assets

Severe Pneumonia →

Recent signals(1)

ClinicalJune 28, 2026

MiNK Therapeutics Trials agenT-797 for Severe Pneumonia with AHRF

MiNK Therapeutics is conducting a clinical trial to assess the efficacy of agenT-797 in combination with standard care for severe pneumonia and acute hypoxemic respiratory failure.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.